{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:22:29Z","timestamp":1790320949678,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1431,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/jto.0b013e3182370e02","type":"journal-article","created":{"date-parts":[[2011,12,15]],"date-time":"2011-12-15T11:35:39Z","timestamp":1323948939000},"page":"203-211","source":"Crossref","is-referenced-by-count":64,"title":["Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)"],"prefix":"10.1016","volume":"7","author":[{"given":"Janessa","family":"Laskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Crin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Gorbunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-liang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus-Peter","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3182370e02_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3182370e02_bib2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials","volume":"311","author":"Non-small Cell Lung Cancer Collaborative Group","year":"2005","journal-title":"BMJ"},{"key":"10.1097\/JTO.0b013e3182370e02_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2004.09.053","article-title":"American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003","volume":"22","author":"Pfister","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1097\/JTO.0b013e3182370e02_bib4","doi-asserted-by":"crossref","first-page":"ii39","DOI":"10.1093\/annonc\/mdn081","article-title":"Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"D'Addario","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib5","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non\u2013small cell lung cancer: a southwest oncology group trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib6","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non\u2013small cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib7","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non\u2013small-cell lung cancer: the TAX 326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib8","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0959-8049(97)10050-8","article-title":"Lung cancer in the elderly","volume":"33","author":"Gridelli","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e3182370e02_bib9","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1200\/JCO.2004.05.031","article-title":"Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-medicare","volume":"22","author":"Ramsey","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib10","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1200\/JCO.2007.12.5435","article-title":"Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database","volume":"25","author":"Owonikoko","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib11","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1200\/JCO.2005.06.742","article-title":"Analysis of treatment practices for elderly cancer patients in Ontario, Canada","volume":"23","author":"Townsley","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1097\/JTO.0b013e3182370e02_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.6-suppl_1-4","article-title":"The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer","volume":"6","author":"Gridelli","year":"2001","journal-title":"Oncologist"},{"key":"10.1097\/JTO.0b013e3182370e02_bib13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jnci\/95.5.362","article-title":"Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial","volume":"95","author":"Gridelli","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e3182370e02_bib14","doi-asserted-by":"crossref","first-page":"8380","DOI":"10.1200\/JCO.2005.01.2781","article-title":"Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group","volume":"23","author":"Sederholm","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2005.07.172","article-title":"Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the cancer and leukemia group B (study 9730)","volume":"23","author":"Lilenbaum","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jnci\/94.3.173","article-title":"Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial","volume":"94","author":"Langer","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e3182370e02_bib17","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/cncr.21495","article-title":"Elderly subgroup analysis of a randomised phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326)","volume":"104","author":"Belani","year":"2005","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3182370e02_bib18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cncr.11548","article-title":"The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel","volume":"98","author":"Hensing","year":"2003","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3182370e02_bib19","doi-asserted-by":"crossref","first-page":"2a","DOI":"10.1200\/jco.2010.28.18_suppl.2","article-title":"Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC)","volume":"28","author":"Quoix","year":"2010","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib20","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3182370e02_bib21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non\u2013small-cell lung cancer: AVAiL","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib22","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin\/gemcitabine and bevacizumab or placebo as first-line therapy for non-squamous non-small cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(10)70151-0","article-title":"Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study","volume":"11","author":"Crin\u00f2","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib24","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2006.09.5570","article-title":"Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR. 10","volume":"25","author":"Pepe","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib25","author":"National Comprehensive Cancer Network (NCCN)"},{"key":"10.1097\/JTO.0b013e3182370e02_bib26","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1097\/JTO.0b013e3181f49c22","article-title":"Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in the phase III BO17704 study (AVAiL)","volume":"5","author":"Leighl","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"12 Suppl","key":"10.1097\/JTO.0b013e3182370e02_bib27","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1002\/cncr.11380","article-title":"Long-term trends in cancer mortality in the United States, 1930\u20131998","volume":"97","author":"Wingo","year":"2003","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3182370e02_bib28","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1378\/chest.117.5.1239","article-title":"Who gets chemotherapy for metastatic lung cancer?","volume":"117","author":"Earle","year":"2000","journal-title":"Chest"},{"key":"10.1097\/JTO.0b013e3182370e02_bib29","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1200\/JCO.2006.09.2759","article-title":"Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups","volume":"25","author":"Kumar","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib30","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3182370e02_bib31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","article-title":"Participation of patients 65 years of age or older in cancer clinical trials","volume":"21","author":"Lewis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182370e02_bib32","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0959-8049(00)00169-6","article-title":"Geriatric oncology: challenges for the new century","volume":"36","author":"Balducci","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e3182370e02_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2007.13.1144","article-title":"Outcomes for elderly, advanced-stage non small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599","volume":"26","author":"Ramalingam","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415317792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415317792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T21:42:15Z","timestamp":1593380535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415317792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1556086415317792"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3182370e02","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}